Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing on the Hong Kong Stock Exchange, positioning itself as an innovative biopharmaceutical company focused on small molecule inhibitors for autoimmune and inflammatory diseases. Founded in 2017, the company has built a diversified pipeline featuring two core clinical-stage products and seven additional candidates spanning novel therapeutic modalities.

Company Profile & Pipeline Overview

Core Product Portfolio

LNK01001 – Oral Second-Generation Selective JAK1 Inhibitor

• Indications: Moderate-to-severe rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, and vitiligo
• Differentiation: Enhanced selectivity profile compared to first-generation JAK inhibitors, potentially improving safety while maintaining efficacy
• Development Stage: Advanced clinical development with multiple Phase II/III trials ongoing

LNK01004 – Topical Soft Pan-JAK Inhibitor

• Indication: Mild-to-moderate atopic dermatitis and other inflammatory skin diseases
• Key Innovation: High local JAK inhibition with minimal systemic exposure, enabling safe long-term topical treatment
• Therapeutic Advantage: Addresses unmet need for chronic inflammatory skin conditions requiring sustained therapy without systemic side effects

Innovative Pipeline Candidates

The pipeline demonstrates Lynk’s strategic evolution from traditional kinase inhibition toward cutting-edge protein degradation technologies, positioning the company at the forefront of next-generation autoimmune therapeutics.

Market Position & Competitive Landscape

• Autoimmune Market Opportunity: Global autoimmune disease therapeutics market projected to reach US$180 billion by 2030, growing at 8.5% CAGR
• JAK Inhibitor Segment: Despite safety concerns with first-generation agents, selective JAK1 inhibitors continue to show strong commercial potential with improved risk-benefit profiles
• Protein Degradation Leadership: Lynk represents one of China’s most advanced companies in applying PROTAC and molecular glue technologies to autoimmune indications, a relatively underexplored application area globally
• Geographic Strategy: Initial focus on China’s large autoimmune patient population (estimated 100+ million patients) with plans for global expansion through partnerships

Financial Outlook & Use of Proceeds

While detailed financials will be disclosed in the final prospectus, industry analysts estimate:

• 2025 Revenue: Primarily from partnerships and licensing (minimal product revenue)
• Cash Runway: Sufficient to advance LNK01001 through regulatory approval and LNK01004 to Phase III completion
• Primary Use of IPO Proceeds:
• 40% – Late-stage clinical development of core products
• 25% – Expansion of protein degradation platform capabilities
• 20% – International clinical trial initiation and regulatory filings
• 15% – Working capital and general corporate purposes

The Hong Kong listing would provide Lynk with enhanced access to international capital markets while maintaining its strategic focus on developing differentiated therapies for high-burden autoimmune and inflammatory conditions.

Forward‑Looking Statements
This brief contains forward-looking statements regarding Lynk Pharmaceuticals’ IPO application, clinical development timelines, and business strategy. Actual results may differ due to risks including regulatory approval of the listing, clinical trial outcomes, competitive dynamics, and execution of the company’s growth strategy.-Fineline Info & Tech